Attovia (ATTO) CBO Zaneta Receives 140,000-Share Award

What Happened
Odrowaz Zaneta, Chief Business Officer of Attovia Therapeutics, was granted a derivative award of 140,000 shares (reported as acquisition code "A") on August 4, 2026. The filing lists an acquisition price of $0.00, so there was no immediate cash paid or proceeds. This is a grant of equity-linked awards (options/RSUs or similar) rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-08-04; Filing date: 2026-08-06 (appears timely — within the typical 2 business‑day Form 4 window).
• Reported acquisition: 140,000 derivative shares at $0.00 (total immediate cash value reported $0).
• Shares owned after transaction: not specified in the provided filing information.
• Footnote (vesting): 25% of the options vest on August 4, 2027; remaining options vest in equal monthly installments over the following 36 months, subject to continued service.
• Transaction code: A = Grant/Award (derivative); no exercise or sale reported.

Context
This is an equity award, not a purchase or sale — it grants potential future economic interest depending on vesting and any future exercise. Such grants are common as compensation for executives; they do not represent immediate liquidity or an immediate bullish/sell signal. The reported $0 acquisition price reflects that the award was granted rather than purchased.